Company
Vox Biomedical, LLC is a new company dedicated to using advanced photonic technologies for drug detection as well as neurological brain monitoring technology based on the use of advanced photonic technologies. Vox personnel have been involved with a wide variety of R&D projects dealing with photonic devices and instrumentation for over 30 years and have exceptional and depth of knowledge in this field. It is currently developing a marijuana breath analyzer under funding from the U.S. Department of Transportation.
Initially, the Vox breath analyzer will focus on the law enforcement market where no road-side device is available for determining intoxication. Once the law enforcement market is developed, the much larger industrial market will be addressed.
Drug testing in the workplace is potentially a larger market for the Vox Breath Analyzer. An estimated 45 to 50 million employees are drug tested each year in the United States, according to 2016 data.
Employees are increasingly testing positive for marijuana, cocaine and methamphetamine at work, driving the rates of positive drug tests in the United States to the highest level in 12 years.
In addition to marijuana, development of an opioid Breath Analyzer using the same basic technology is being explored. Cerebral oximetry instrumentation is also being developed for medical purposes for sensing neurological brain function.
Our Goal
We empower human safety and well-being through photonics-based diagnostic technologies, including drug testing diagnostics on the road, and in the workplace.
Company History
Vox Biomedical is a new company dedicated to using advanced photonic technology for drug detection. Vox is formed by a group of scientists, engineers and high-tech executives in Bedford, MA.
From our Chief Technology Officer to our staff scientists and support engineers, everyone at Vox has hands-on experience in both the manufacturing of optical components and the development of new products.
Our leader, Roger Little, brings a strong technology background with significant experience in solar, semiconductor, and biomedical fields, which will help Vox to meet the increasing demand for optoelectroncis and spectroscopy for detection and medical applications. Most recently, he was president and CEO of Spire Corporation and CTO of N2 Biomedical.
What we do
- Roadside breath analyzer (no swabs). Our device is designed for ease of use, maintenance and accuracy.
- Workplace breath analyzer for drug detection
- Cerebral oximetry instrumentation
Why we do it
To address, and eliminate the threat of unsafe roads and workplaces.
“You may have the holy grail of drug testing, if you can create a breath instrument that can accurately detect the presence of THC.”
Phoenix Police Dept Crime Lab
Meet the Team
Roger Little, Vox CEO
Mr. Little led the Spire Corporation’s business activities for 46 years in the defense, solar, optoelectronics and biomedical industries. During this time, he managed contract research, capital equipment, processing services development and semiconductor operations. Mr. Little lead Spire’s IPO and Nasdaq market presence for 25 years and was the principal architect of the N2 Biomedical and Spire Semiconductor spin-offs. Mr. Little holds an MS in Geophysics and has numerous patents and publications. He has had extensive advisory group participation with DOE, DOD and NSF.
Arash Aslani, VP/GM
Arash Aslani brings more than 15 years of experience in leading biomedical innovation for R&D projects. Mr. Aslani was R&D Manager of N2 Biomedical for seven years prior to joining Vox Biomedical. He directed and participated in several government funded projects from NIH, NASA and DOT during his time at N2. He was a key member to establish the N2 Biomedical’s R&D group with seven technical members in 2013. N2’s R&D group was awarded several grants and contracts including three phase II programs during his time. Before joining N2, he was in the Biomedical Division of Spire Corporation, where he performed a wide range of research on biomaterials, infrared fiber lasers and nanomaterials for applications ranging from orthopedic, dental, vascular access and high-performance lasers.
Dr. Kurt Linden, Senior Scientist
Dr. Linden is a leading expert on the development and application of semiconductor photonic devices such as LEDs, lasers and detectors, as well as their utilization in instrumentation, covering the spectral region extending from UV through far-infrared (terahertz). He has developed diode laser-pumped infrared fiber lasers for myringotomy and middle-ear surgery and worked on a new watt-level 420 nm blue diode laser, quantum cascade lasers emitting in the terahertz spectral region, VCSELS for low-cost near-IR applications, cerebral oximetry instrumentation for monitoring homological brain fluids, infrared detections for military applications and manufacturing processes associated with these products.
Dr. Scott Lukas, Scientific Advisor
Director of McLean Imaging Center and Professor of Psychiatry (Pharmacology)
Dr. Lukas has been conducting both laboratory studies and randomized clinical trials of drug and alcohol abuse, sleep disorders and psychiatric disorders using a variety of imaging modalities since 1982. His major area of research has been to study the effects of various drugs of abuse including opiates, marihuana, alcohol, cocaine, sedative/hypnotics and nicotine as well as their interactions and developing medications to treat drug and alcohol abuse/dependence.